ProImmune Opens New Global Headquarters in Oxford
The 18,000-sq-ft facility will support the expansion of immunogenicity testing and target binding technologies.
The 18,000-sq-ft facility will support the expansion of immunogenicity testing and target binding technologies.
Teams complete whole human genome sequencing and analysis in under four hours, demonstrating potential for same-day NICU workflows.
The update introduces presentation queues, enhanced consult workflows, and speech-driven dictation capabilities for pathology labs.
New TheraPEAK products include mammalian-derived cytokines for immune cell expansion and chemically defined medium for AAV production.
Findings show that early symptom patterns and biomarker data may help forecast which mild traumatic brain injury patients will experience 30-day symptom persistence.